TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVJFDrugs in Pipeline
18
Phase 3 Programs
12
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
TEV-53408 Phase 2 Est. Readout
Estimated primary completion for TEV-53408 trial (NCT06807463) in Celiac Disease. Topline data typically follows completion by weeks to months.
Hit key Phase IIa endpoint
SourceHow TEVJF's past catalysts played out
Fasinumab
Osteoarthritis, Knee
FS MDPI
Asthma
TEV-50717
Tourette Syndrome
TV-46000
Schizophrenia
Fremanezumab
Migraine
Laquinimod
Lupus Arthritis
Reslizumab
Eosinophilic Asthma
Glatiramer Acetate
Optic Neuritis
Beclomethasone dipropionate
Rhinitis, Allergic, Perennial
ACR16
Huntington's Disease
Hydrocodone ER
Chronic Pain
Rasagiline Mesylate
Parkinson's Disease
Omacetaxine mepesuccinate
Chronic Myeloid Leukemia
TP-38
Glioblastoma Multiforme
Fp MDPI
Asthma
Talampanel
Epilepsy
TEV-56286
Multiple System Atrophy
TV-45070
Osteoarthritis of the Knee
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Fasinumab | Phase 3 | Osteoarthritis, Knee | - | - |
FS MDPI | Phase 3 | Asthma | - | - |
TEV-50717 | Phase 3 | Tourette Syndrome | - | - |
TV-46000 | Phase 3 | Schizophrenia | - | - |
Fremanezumab | Phase 3 | Migraine | - | - |
Laquinimod | Phase 3 | Lupus Arthritis | - | - |
Reslizumab | Phase 3 | Eosinophilic Asthma | - | - |
Glatiramer Acetate | Phase 3 | Optic Neuritis | - | - |
Beclomethasone dipropionate | Phase 3 | Rhinitis, Allergic, Perennial | - | - |
ACR16 | Phase 3 | Huntington's Disease | - | - |
Hydrocodone ER | Phase 3 | Chronic Pain | - | - |
Rasagiline Mesylate | Phase 3 | Parkinson's Disease | - | - |
Omacetaxine mepesuccinate | Phase 2 | Chronic Myeloid Leukemia | - | - |
TP-38 | Phase 2 | Glioblastoma Multiforme | - | - |
Fp MDPI | Phase 2 | Asthma | - | - |
Talampanel | Phase 2 | Epilepsy | - | - |
TEV-56286 | Phase 2 | Multiple System Atrophy | - | - |
TV-45070 | Phase 2 | Osteoarthritis of the Knee | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in TEVA PHARMACEUTICAL INDUSTRIES LTD's drug pipeline?→
CatalystAlert tracks 18 drug candidates in TEVA PHARMACEUTICAL INDUSTRIES LTD's (TEVJF) pipeline across Phase 3, Phase 2. Its lead program is Fasinumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TEVA PHARMACEUTICAL INDUSTRIES LTD's next FDA catalyst?→
TEVA PHARMACEUTICAL INDUSTRIES LTD's (TEVJF) next tracked catalyst is a Offering expected September 8, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TEVJF biotech catalysts?→
Add TEVJF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TEVA PHARMACEUTICAL INDUSTRIES LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.